Non-Alcoholic Steatohepatitis (NASH) Market Revenue to Touch $21,478 Million by 2025 | Trends and Strategy Analysis
Non-alcoholic steatohepatitis (NASH) market study provides an in-depth analysis along with the current trends and future estimations.
PORTLAND, OREGON, UNITED STATES, May 31, 2023/EINPresswire.com/ -- Non-alcoholic steatohepatitis (NASH), is a common liver disease, often called as silent liver disease. It is asymptomatic until its later stages, and thus many patients are unaware of their condition. NASH is projected to lead the cause of liver transplantation in the U.S. in the coming years. Some major factors such as higher prevalence of NASH, expected launch of pipeline drugs, and higher number of unmet needs drive the growth of this market. However, poor diagnosis of NASH due to the lack of ideal diagnostic technologies limit the growth of the NASH market. Non-alcoholic steatohepatitis (NASH) market was valued at $1,179 million in 2017, and is expected to reach $21,478 million by 2025, growing at a CAGR of 58.4% from 2021 to 2025.
๐๐ข๐ฌ๐ญ ๐จ๐ ๐๐๐ฒ ๐๐ฅ๐๐ฒ๐๐ซ๐ฌ :
Allergan Plc (Tobira Therapeutics Inc.), Cadila Healthcare Ltd., Conatus Pharmaceuticals, Inc., Galmed Pharmaceuticals Ltd., Gemphire Therapeutics Inc., Genfit SA, Gilead Sciences, Inc., Intercept Pharmaceuticals, Inc., Novartis International AG, Shire plc
๐๐จ๐ฐ๐ง๐ฅ๐จ๐๐ ๐๐๐ฆ๐ฉ๐ฅ๐ ๐๐๐ฉ๐จ๐ซ๐ญ https://www.alliedmarketresearch.com/request-sample/224
The Non-Alcoholic Steatohepatitis (NASH) market can be segmented in several ways based on various factors. Here are some common segmentation approaches:
Disease Stage: NASH can be classified into different stages based on the severity of liver inflammation and fibrosis. The stages often used are F0 to F4, with F0 indicating no fibrosis and F4 indicating cirrhosis. This segmentation helps in understanding the progression of the disease and the appropriate treatment approaches for each stage.
Drug Class: The NASH market can be segmented based on the different drug classes used in the treatment of NASH. Currently, there is no FDA-approved medication specifically for NASH, but various drug classes are being investigated, including insulin sensitizers, antioxidants, anti-fibrotic agents, and others. This segmentation helps in understanding the different treatment options available and the companies developing drugs in each class.
End User: Another way to segment the NASH market is by the end users or stakeholders involved. This can include hospitals, clinics, research institutions, and pharmaceutical companies. Understanding the different stakeholders in the market helps in assessing the demand for diagnostic tests, drugs, and other products related to NASH.
Geography: The NASH market can also be segmented based on geographical regions, such as North America, Europe, Asia Pacific, and Rest of the World. This segmentation helps in analyzing the prevalence of NASH in different regions, the regulatory environment, and the market potential in each geographic area.
Diagnostic Tests: Diagnostic tests play a crucial role in identifying and monitoring NASH. The market can be segmented based on different diagnostic tests, such as liver biopsy, imaging techniques (ultrasound, MRI, CT scan), blood tests (liver enzymes, liver function tests, biomarkers), and non-invasive tests (fibroscan, elastography). This segmentation helps in understanding the demand for diagnostic tests and the companies offering these tests.
๐ ๐จ๐ซ ๐๐ฎ๐ซ๐๐ก๐๐ฌ๐ ๐๐ง๐ช๐ฎ๐ข๐ซ๐ฒ https://www.alliedmarketresearch.com/purchase-enquiry/224
๐๐๐๐๐ ๐๐๐๐๐๐๐๐๐๐๐๐ ๐๐๐๐๐๐๐ ๐๐ ๐๐๐ ๐๐๐๐๐๐:
Powered with Complimentary Analyst Hours and Expert Interviews with Each Report
Comprehensive quantitative and qualitative insights at segment and sub-segment level
Covid 19 impact trends and perspective
Granular insights at global/regional/country level
Deep-rooted insights on market dynamics (drivers, restraints, opportunities) and business environment
Blanket coverage on competitive landscape
Winning imperatives
Exhaustive coverage on โStrategic Developmentsโ registered by leading players of the market
๐๐ญ๐ก๐๐ซ ๐๐ซ๐๐ง๐๐ข๐ง๐ ๐๐๐ฉ๐จ๐ซ๐ญ๐ฌ:
Compression Therapy Market -- https://www.alliedmarketresearch.com/compression-therapy-market
Asia Hospital-Acquired Infection Diagnostics Market -- https://www.alliedmarketresearch.com/asia-pacific-hospital-acquired-infection-diagnostics-market-A08861
๐๐๐๐๐๐- ๐ ๐๐ฎ๐๐ฌ๐๐ซ๐ข๐ฉ๐ญ๐ข๐จ๐ง-๐๐๐ฌ๐๐ ๐๐ข๐๐ซ๐๐ซ๐ฒ (๐๐ซ๐๐ฆ๐ข๐ฎ๐ฆ ๐จ๐ง-๐๐๐ฆ๐๐ง๐, ๐ฌ๐ฎ๐๐ฌ๐๐ซ๐ข๐ฉ๐ญ๐ข๐จ๐ง-๐๐๐ฌ๐๐ ๐ฉ๐ซ๐ข๐๐ข๐ง๐ ๐ฆ๐จ๐๐๐ฅ) ๐๐๐๐๐ซ๐๐ ๐๐ฒ ๐๐ฅ๐ฅ๐ข๐๐ ๐๐๐ซ๐ค๐๐ญ ๐๐๐ฌ๐๐๐ซ๐๐ก:
AMR introduces its online premium subscription-based library Avenue, designed specifically to offer cost-effective, one-stop solution for enterprises, investors, and universities. With Avenue, subscribers can avail an entire repository of reports on more than 2,000 niche industries and more than 12,000 company profiles. Moreover, users can get an online access to quantitative and qualitative data in PDF and Excel formats along with analyst support, customization, and updated versions of reports.
๐๐๐ญ ๐๐ง ๐๐๐๐๐ฌ๐ฌ ๐ญ๐จ ๐ญ๐ก๐ ๐ฅ๐ข๐๐ซ๐๐ซ๐ฒ ๐จ๐ ๐ซ๐๐ฉ๐จ๐ซ๐ญ๐ฌ ๐๐ญ ๐๐ง๐ฒ ๐ญ๐ข๐ฆ๐ ๐๐ซ๐จ๐ฆ ๐๐ง๐ฒ ๐๐๐ฏ๐ข๐๐ ๐๐ง๐ ๐๐ง๐ฒ๐ฐ๐ก๐๐ซ๐. ๐ ๐จ๐ซ ๐ฆ๐จ๐ซ๐ ๐๐๐ญ๐๐ข๐ฅ๐ฌ, ๐๐จ๐ฅ๐ฅ๐จ๐ฐ ๐ญ๐ก๐ ๐ฅ๐ข๐ง๐ค: https://www.alliedmarketresearch.com/library-access
๐๐๐จ๐ฎ๐ญ ๐๐ฅ๐ฅ๐ข๐๐ ๐๐๐ซ๐ค๐๐ญ ๐๐๐ฌ๐๐๐ซ๐๐ก:
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domains. AMR offers its services across 11 industry verticals including Life Sciences, Consumer Goods, Materials & Chemicals, Construction & Manufacturing, Food & Beverages, Energy & Power, Semiconductor & Electronics, Automotive & Transportation, ICT & Media, Aerospace & Defense, and BFSI.
We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of the domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.
David Correa
Allied Analytics LLP
+ 1-800-792-5285
email us here
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
